LGC, Biosearch Technologies, manufacturer and inventor of mission-critical dyes and components for diagnostic kits, and QuantuMDx, a life sciences company developing transformational point-of-care molecular diagnostics, are working together on the supply of a SARS-CoV-2 assay for laboratory use, and which delivers a result in approximately 70 minutes.
The sensitive test targets three SARS-Cov-2 genomic loci; the S, N and Orf1 genes and can run on multiple high- and low-throughput PCR platforms that can be calibrated for the fluorophores FAM and HEX. As all the assay reagents are lyophilised in a single tube, the assay is more convenient for shipping than liquid based assay kits.
Brian Kim, President and Managing Director at LGC, Biosearch Technologies, said, “We are the inventor of mission critical components that are being recommended for use in kits for diagnosis and surveillance. In times like this, we need to enable laboratories to move fast and safely. Collaborating with QuantuMDx allows labs to roll out a diagnostic solution in a robust and standardized setting that requires virtually no eyes-on time.”
Colin Toombs, VP R&D at QuantuMDx, said: “To support national and international efforts to tackle COVID-19, we needed to act fast, secure our supply chain and scale up at speed. Working with LGC, Biosearch Technologies we have been able to expedite our product development and have established an ongoing partnership for the future.”
LGC, Biosearch Technologies has been working closely with suppliers and customers – such as Co-Diagnostics, LifeRiver and UgenTec – in order to expedite detection solutions and ensure they are available where and when necessary.